This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Myasthenia Gravis and Related Disorders I

Edited by Edited by Gil I. Wolfe (University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York), Matthew N. Meriggioli (University of Illinois College of Medicine at Chicago, Chicago, Illinois), Emma Ciafaloni (University of Rochester, Rochester, New York), and Robert L. Ruff (Louis Stokes Cleveland Department of Veterans Affairs Medical Center and Case Western Reserve University, Cleveland, Ohio)
Myasthenia Gravis and Related Disorders I

Published: December 2012

Volume 1274

Learn More

Myasthenia gravis (MG), an acquired immune syndrome affecting proteins at the neuromuscular junction, causes significant muscular functional impairment and can compromise patients’ quality of life, including fatigue, disability, and increased mortality rates. Continued efforts in the last decades have begun to produce significant progress in our understanding of this rare condition, yet considerable challenges remain for improving diagnosis and developing effective treatments for MG. The present volume comprises papers stemming from the “12th International Conference on Myasthenia Gravis and Related Disorders,” held May 21–23, 2012 at the New York Academy of Sciences in New York City. The papers collected in this first of two Annals volumes highlight some of the key developments in neuroscience and immunology in MG and related syndromes presented at the conference, including structure and function of the neuromuscular junction, advances in immunology and their relationship to myasthenia gravis, clinical and laboratory developments, outcome measurements and clinical trial development, and animal models of neuromuscular junction disease.